InMode Ltd. (NASDAQ:INMD) Shares Sold by Meitav Investment House Ltd.

Meitav Investment House Ltd. lowered its stake in shares of InMode Ltd. (NASDAQ:INMD) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,334,405 shares of the healthcare company’s stock after selling 17,403 shares during the quarter. Meitav Investment House Ltd. owned about 1.59% of InMode worth $22,269,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Systematic Financial Management LP grew its holdings in InMode by 13.3% in the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock valued at $16,647,000 after purchasing an additional 115,492 shares during the period. Barclays PLC grew its stake in shares of InMode by 113.5% during the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after buying an additional 90,173 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of InMode by 54.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock worth $2,127,000 after buying an additional 44,058 shares during the last quarter. State Street Corp increased its holdings in shares of InMode by 3.7% during the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock worth $34,657,000 after buying an additional 73,183 shares during the last quarter. Finally, Atlas Legacy Advisors LLC purchased a new position in shares of InMode in the 4th quarter worth $848,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on INMD. Barclays boosted their price target on InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, InMode presently has an average rating of “Hold” and a consensus target price of $22.25.

InMode Price Performance

Shares of INMD opened at $19.40 on Thursday. InMode Ltd. has a 12 month low of $14.87 and a 12 month high of $23.46. The stock has a market cap of $1.35 billion, a PE ratio of 8.26 and a beta of 2.13. The stock’s 50-day moving average is $17.36 and its two-hundred day moving average is $17.26.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.